Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
As of September 9, 2026, Eris Lifesciences Limited entered into a term loan agreement with Axis Bank Limited for ₹45 crore to meet other liabilities. This drawdown brings the total outstanding loan balance to ₹210.77 crore. The company stated this is a routine financial adjustment and will not impact the expected net debt for the quarter.
Mr. Krishnakumar Vaidyanathan resigned as Executive Director and Chief Operating Officer (COO) of Eris Lifesciences Limited, effective September 30, 2026. This resignation was accepted by the Chairman, and the cessation event was disclosed on September 11, 2026.
As of September 18, 2026, Eris Lifesciences has shown the following returns: a 1% return in the last day, a 1% return over the last 10 days, a -2% return over the last month, a -8% return over the last three months, and a 1% return over the last six months. Over the past year, the stock has returned -19%, and year-to-date, it has returned -12%.
On a daily basis, the stock's closing price was ₹1321.3, with the 20-day Exponential Moving Average (EMA) at ₹1327.18 and the 50-day EMA at ₹1351.68. The Supertrend indicator is showing a bearish direction at ₹1388.18. On a monthly basis, the Supertrend is bullish at ₹751.99, with the 20-day EMA at ₹1395.66. The weekly trend shows a bearish Supertrend at ₹1550.11 and a 20-day EMA of ₹1372.46.
As of 18 Sept 2026, 03:30 pm
Showing 3 of 14 candles
Recent drawdown or price variability is high enough to warrant closer monitoring.
Primary driver: Price remains materially below a previous peak
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
Downward price movement of 4.01 standard deviations recorded on 2026-09-15.
Unusual market activity that may warrant review of the underlying price, volume, or news context.
The session opened materially above the previous close, indicating a sharp repricing at the open.
The move may reflect new information; subsequent price follow-through is worth monitoring.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | PEAK₹873.25 crore | ₹756.56 crore | ₹807.45 crore | ₹792.41 crore | ₹773 crore |
| Finance Costs | ₹46.65 crore | ₹45.62 crore | ₹48.82 crore | PEAK₹49.55 crore | ₹48.68 crore |
| Other Expenses | PEAK₹184.36 crore | ₹160.89 crore | ₹164.46 crore | ₹164.34 crore | ₹167.22 crore |
| Profit Before Exceptional Items And Tax | PEAK₹179.89 crore | ₹160.61 crore | ₹162.47 crore | ₹172.39 crore | ₹160.21 crore |
| Profit Before Tax | PEAK₹179.89 crore | ₹160.61 crore | ₹145.23 crore | ₹172.39 crore | ₹160.21 crore |
| Tax Expense | ₹36.17 crore | -₹119.69 crore | ₹36.52 crore | PEAK₹38.20 crore | ₹36 crore |
Eris Lifesciences Limited reported a sharp increase in revenue for the quarter ended 30 June 2026 (Q1 FY2026-27). Revenue from operations rose to ₹873.25 crore, marking the highest quarterly top line in the five quarters shown. Profit before tax grew in line with revenue, while net profit rose 14.56% as tax expenses normalised. Profitability margins were largely unchanged from a year ago.
Revenue from operations was ₹873.25 crore, up 12.97% from ₹773 crore in Q1 FY2025-26 and 15.42% higher than ₹756.56 crore in the immediately preceding quarter (Q4 FY2025-26). The sequential increase reversed a 6.3% quarter-on-quarter decline in Q4 FY2025-26 and represents the highest quarterly revenue among the five periods provided.
Basic earnings per share from continuing operations was ₹10.28, compared to ₹8.66 in Q1 FY2025-26 (an increase of 18.71%). Diluted earnings per share rose from ₹8.64 to ₹10.26 over the same period.
Exchange disclosures and regulatory announcements for Eris Lifesciences.
Mr. Krishnakumar Vaidyanathan resigned as Executive Director & Chief Operating Officer (COO) of Eris Lifesciences Limited, effective from the close of business hours on September 30, 2026, to pursue professional opportunities outside the organization. The resignation was accepted by the Chairman.
Eris Lifesciences Limited reported the resignation of Executive Director Krishnakumar Vaidyanathan, effective September 30, 2026. The cessation event was disclosed on September 11, 2026, at 11:00 AM, marking a change in the company's board composition.
Eris Lifesciences Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA
Eris Lifesciences Limited has entered into a term loan agreement with Axis Bank Limited for ₹45 crore, drawn on 09 September 2026, to meet other liabilities. The loan will be secured by a charge on the company’s brands. The company states this is a routine financial adjustment that will not affect the expected net debt figure for the quarter.
On September 9, 2026, Eris Lifesciences Limited executed a term loan agreement with Axis Bank Limited to draw down ₹45 crores for meeting other liabilities. The transaction involves unrelated parties and is secured by a charge on the company's brands. Following this drawdown, the total outstanding loan balance stands at ₹210.77 crores.
On September 7, 2026, Eris Lifesciences Limited notified stock exchanges of a scheduled one-on-one meeting with Bank of India Mutual Fund on September 10, 2026, at 3:30 PM IST. The in-person session will be conducted by Mr. Krishnakumar Vaidyanathan and is restricted to publicly available information without the disclosure of unpublished price-sensitive data.
Eris Lifesciences Limited, Glottis Logistics Limited, GFL Limited, Aster DM Quality Care Limited, and VRL Logistics Limited have announced their respective Annual General Meetings to be held via Video Conferencing without physical presence on September 25, 28, or 29, 2026. The meetings cover the Financial Year 2025-26 and are conducted in compliance with Ministry of Corporate Affairs Circulars and SEBI Listing Regulations. Shareholders are provided remote e-voting facilities starting from late September 2026, with record dates set for September 22, 2026, for most entities.
Eris Lifesciences Limited will hold its 20th Annual General Meeting on September 25, 2026, at 11:00 AM via video conferencing. The meeting will consider adopting audited financial statements for FY ended March 31, 2026, re-appoint Mr. Kaushal Kamlesh Shah as a director retiring by rotation, ratify cost auditor remuneration of Rs. 3,66,000 for M/s. Kiran J Mehta & Co. for FY 2026-27, and re-appoint Mr. Sujesh Vasudevan as an Independent Director for a second term from July 25, 2027 to July 24, 2032.
Recent market and company developments associated with Eris Lifesciences.
Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance.
V Krishnakumar, Eris Lifesciences, Biological E, BE BioSol, Eris Lifesciences COO, Biological E CEO, CDMO business, biopharma, vaccine manufacturers, pharma leadership, Krishnakumar resignation, Eris Lifesciences resignation
Private equity firm ChrysCapital is set to acquire a significant stake in Linux Laboratories. This deal will see existing investor Tata Capital Healthcare Fund exit its entire holding. Linux Laboratories focuses on central nervous system therapies and has a strong brand portfolio. The company anticipates robust revenue and Ebitda growth in the coming years. This acquisition highlights continued private equity interest in India's pharmaceutical sector.
Sensex, Nifty, Share Prices LIVE: Sensex was up 160.95 pts or 0.20% to 78,741.95 at 9.16 am after opening at 78,782.43 from the previous close of 78,581; Nifty inched up 8.70 pts or 0.04% to 24,633.35.
The drugmaker reported double-digit growth in revenue and profit for the June quarter, even as rising costs squeezed operating margins.
Sensex Today | Stock Market LIVE Updates: We are the halfway mark of the day's trade, and the bulls look in a strong position. The markets are on the rise, and are trading on a strong footing. The Nifty up over 240 points, jumping to 24,200. The Nifty Bank index is up 400 points, rising to 57,000. Infosys, Larsen & Toubro and HUL are the top gainers.
Comprehensive Section Breakdown for Eris Lifesciences
Strategic Vision: Pharmaceutical company developing and marketing branded formulations for chronic diseases.
• Vertically integrated pharmaceutical operations with WHO-GMP approved manufacturing facilities.
• Extensive distribution network across India.
• Strategic acquisitions to expand into new therapeutic areas and product segments.
Profit before tax (PBT) came in at ₹179.89 crore, a 12.28% rise from ₹160.21 crore a year ago. The PBT margin was 20.6% of revenue, essentially unchanged from 20.7% in the year-ago quarter. Net profit after tax increased to ₹143.32 crore, up 14.56% from ₹125.10 crore in Q1 FY2025-26. The net profit margin moved from 16.2% to 16.4%. The sequential comparison with Q4 FY2025-26 is distorted by an unusual negative tax expense of ₹119.69 crore in that period, which had inflated net profit to ₹279.10 crore. The current quarter’s tax expense of ₹36.17 crore returned to a level consistent with the company’s typical quarterly tax outlays.
Total expenses (excluding other income) were ₹695.75 crore. Key components included:
The quarter delivered a significant increase in revenue, with the top line reaching its highest level in the five periods shown. Profit before tax grew at a similar pace, and margins remained broadly stable. The 15.4% sequential rebound after a 6.3% decline the prior quarter was notable. Finance costs declined year-on-year but ticked up from the immediate prior quarter. Overall, the results show a strong start to the fiscal year, with both revenue and profitability moving higher while cost ratios held steady.
Category: Pharmaceuticals
Focuses on addressing chronic and sub-chronic diseases, with a core presence in the cardio-metabolic therapeutic area.
Category: Pharmaceuticals
Includes oral anti-diabetic medications and insulin products.
Category: Pharmaceuticals
Products aimed at managing cardiovascular health.
Category: Pharmaceuticals
Nutritional supplements and products.
Category: Pharmaceuticals
Expanding into dermatology, gynaecology, neuroscience, nephrology, oncology, and critical care.
Category: Pharmaceuticals
Segment includes sterile injectables, acquired through Swiss Parenterals, and branded injectables in critical care.
Category: Pharmaceuticals
Entry into the oncology segment with a portfolio of monoclonal antibodies.
Core Thesis: The company engages with the market through patient care initiatives and India-centric studies to support physician management of patient health.
• Patient Care Initiatives (PCI): This platform delivers advanced diagnostic and monitoring technologies to patients, providing insights to support physicians in managing health outcomes. • India-Centric Studies: The company conducts studies to generate and utilize India-specific data relevant to the diagnosis and management of cardio-metabolic conditions.